Article · 29 Aug 2026
Conference abstract
Prevention of estrogenindependent breast cancer using her family targeted dendritic cell vaccines
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
ntroduction: HER-2/neu over-expression in breast cancer is associated with high risk of recurrence and poorer outcomes. HER-2/neu expression has been identifi ed in breast cancer stem cells. Elimination of HER-2/neu-expressing ce lls may therefore improve breast cancer outcomes. Methods: Twenty-seven patients with HER-2/neu over-expressing ductal carcinoma in situ (DCIS) were enrolled in a phase I neoadjuvant trial to determine whether HER-2/neu peptide- pulsed DC vaccines were safe and could e liminate HER-2/neu over-expressing cells. Pre- and post- vaccination immune monitoring and histopathological analysis were conducted to assess results. Results: Post-immunization, anti-HER-2/neu CD4 pos and CD8 pos T cells were identifi ed in >88% of subjects, with evidence of durable (>2 yr) responses and inter-molecular epitope spreading. Five of 27 (18.5%) vaccinated subjects had no evidence of remaining disease. Detectable HER-2/neu was eliminated (i.e. immunoedited) in 11 of 22 (50%) patients with residual DCIS. Comparing the 10 ERneg with the17 ER pos subjects we observed: no residual DCIS in 40% vs. 5.9% of patients, and sustained HER-2/neu expression in 10% vs. 47.1%, suggesting vaccination was more eff ective against hormone-independent DCIS (p=0.04). Post- vaccination DCIS phenotypes also diff ered signifi cantly between ERpos and ER neg subjects (p=0.01). Seven of 16 patients (43.8%) initially presenting with the more aggressive ER pos HER- 2/neu pos phenotype demonstrated ER pos HER-2/neu neg phenotype aft er vaccination, while 3 of 6 (50%) starting with ER neg HER-2/neu pos DCIS became ER neg HER-2/neu neg . Conclusions: Th is targeted immunoediting approach appeared eff ective for reducing HER-2/neu-expressing cells in DCIS, suggesting that targeting HER-2/neu and other stem cell- associated molecules should be explored for preventing primary and recurrent breast cancer. PDF HTML
Keywords
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Vaccines & Vaccination.
Article · 29 Aug 2026
Advances in Adjuvant Development for Enhanced Vaccine Performance and Long-Term Immune Protection
Article · 20 Jun 2026
Herd Immunity and Its Role in Controlling Infectious Diseases
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vaccines & Vaccination
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Brian J Czern”